shares soared Wednesday after the company said federal regulators have approved its HIV-detection test.
Shares rose $1.96, or 25.4%, to $9.67 in unusually heavy trading. About five times the normal daily volume of 866,272 shares had already changed hands.
The Bethlehem, Pa.-based company said the Food and Drug Administration had approved its OraQuick Rapid HIV-1/2 antibody test for use in detecting antibodies to what is known as HIV-2 in oral fluid samples.
The company says an estimated 40 million people currently have the HIV virus. The FDA has already approved a similar test for HIV-1.